上海医药：替格瑞洛片的 ANDA 获得美国 FDA 批准

Group 1 - The core point of the article is that Changzhou Pharmaceutical Factory has received final approval from the FDA for its abbreviated new drug application (ANDA) for Ticagrelor tablets, which is significant for expanding the company's overseas market presence [1][2] - The drug Ticagrelor is used for patients with acute coronary syndrome to reduce the incidence of thrombotic cardiovascular events and was originally developed by AstraZeneca, launched in the U.S. in 2011 [1] - The company has invested approximately RMB 9.6713 million in research and development for this drug as of the announcement date [1]